Search
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedPatients with LEMS develop serum antibodies against presynaptic P/Q-type voltage-gated calcium channels, leading to decreased presynaptic calcium levels and reduced quantal release of acetylcholine, which
Tropisetron
go.drugbank.com/drugs/DB11699ApprovedInvestigationalWithdrawnAs a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cho...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRifamycin
go.drugbank.com/drugs/DB11753ApprovedInvestigationalWithdrawnRifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDanoprevir
go.drugbank.com/drugs/DB11779InvestigationalDanoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsEsketamine
go.drugbank.com/drugs/DB11823ApprovedInvestigationalMajor depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...
Categories: NMDA Receptor Antagonists, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor AntagonistsValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesElagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Gonadotropin Releasing Hormone Receptor Antagonists, Cytochrome P-450 SubstratesThiamylal
go.drugbank.com/drugs/DB01154ApprovedVet approvedA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers